Evidence map›Paper›PMID 42785297›Full record

ReviewCell stem cell2026

Immunoids: Building immunocompetent organoids from human pluripotent stem cells.

Colin O'Hern, Zachary Miller, Mia Dionise, Satyajit Hari Kulkarni, Christopher H Contag, Aitor Aguirre

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell stem cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Colin O'HernInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA; College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Zachary MillerInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA; College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Mia DioniseInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA; College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Satyajit Hari KulkarniInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI, USA; College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Christopher H ContagInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA; Department of Microbiology, Genetics and Immunology, Michigan State University, East Lansing, MI, USA.
Aitor AguirreInstitute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA. Electronic address: aaguirre@msu.edu.

Funding

Oxylipin Signaling in Congenital Heart DiseaseR01HL151505 · NHLBI · MICHIGAN STATE UNIVERSITY · PI AGUIRRE, AITOR · 2021 to 2025
$2.2M
Lipid signaling in cardiac development and diseaseK01HL135464 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AGUIRRE, AITOR · 2017 to 2021
$795k
American Heart Association-American Stroke Association 19IPLOI34660342NHLBI NIH HHS K01 HL135464NHLBI NIH HHS R01 HL151505
6 · The paper itself

Abstract

Pluripotent stem cell-derived immunocompetent organoids and assembloids, termed here "immunoids," are becoming important human models for studying immune-tissue interactions. Advances across organ systems now include incorporation of mature and immature immune populations into multiple organoid types, multilineage differentiation, and endogenous immune co-development. Defining standards for immunoid fabrication will be essential for improving physiological modeling and clinical translation. In the coming years, as these platforms mature, immunoids are poised to transform research by advancing our understanding of human development, disease mechanisms, and therapeutic responses, becoming a cornerstone of precision medicine.

Indexed as

OrganoidsPluripotent Stem CellsAnimalsCell DifferentiationHumansassembloiddevelopmentdisease modelshuman pluripotent stem cellsimmuneimmunoidnew alternative methodologiesorganoidself-organizationstem cell engineering

Identifiers

PMID42785297
PMCPMC13614519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.